ARTICLE | Clinical News
OSI-774 (CP-358,774): Began Phase Ib trial
March 19, 2001 8:00 AM UTC
OSI Pharmaceuticals Inc. (OSIP), Uniondale, N.Y. Product: OSI-774 (CP-358,774) Business: Cancer Therapeutic category: Receptor antagonist Target: EGFR Description: Oral small molecule inhibitor of th...